Treatment-naive patients with advanced follicular lymphoma who received a combination of rituximab plus lenalidomide appeared to have similar outcomes as patients treated with rituximab and ...

Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated through multiple types of immune cells found in the tumor microenvironment, ...

Rituximab is a chimeric human/mouse monoclonal antibody that is approved for the treatment of relapsed and refractory non-Hodgkin's lymphoma (NHL) and in combination with CHOP (cyclophosphamide ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in patients with asymptomatic, low tumour burden follicular lymphoma.

To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 ...

Among patients with relapsed or refractory follicular lymphoma (FL), the treatment combination of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been found to ...

The first biosimilar rituximab for use in non-Hodgkin's lymphoma (NHL) has been approved in the United States by the Food and Drug Administration (FDA). Rituximab, a monoclonal antibody directed ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the Phase III study CHRONOS-3 evaluating Aliqopa™ (copanlisib) in combination with rituximab in indolent Non-Hodgkin's Lymphoma (iNHL ...

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma Provided by ACCESS Newswire May 14, 2025, 1:40:00 PM ...

Potential Positives. 64% complete response rate with AlloNK + rituximab in heavily pretreated B-cell non-Hodgkin lymphoma patients, comparable to approved auto-CAR-T therapies.

The primary outcome of time to next treatment (TTNT) was not yet reached (95% CI 15.6-not estimable) in the maintenance group, 14.8 years (95% CI 7.5-not reached) in the induction group, and 5.6 ...

Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated through multiple types of immune cells found in the tumor microenvironment, ...